GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Piotroski F-Score

Translate Bio (Translate Bio) Piotroski F-Score : 6 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Translate Bio has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Translate Bio's Piotroski F-Score or its related term are showing as below:

TBIO' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 6

During the past 5 years, the highest Piotroski F-Score of Translate Bio was 6. The lowest was 3. And the median was 5.


Translate Bio Piotroski F-Score Historical Data

The historical data trend for Translate Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Piotroski F-Score Chart

Translate Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
N/A N/A 5.00 3.00 5.00

Translate Bio Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 5.00 6.00

Competitive Comparison of Translate Bio's Piotroski F-Score

For the Biotechnology subindustry, Translate Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Translate Bio's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Translate Bio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Net Income was 17.344 + -20.561 + 26.522 + 17.144 = $40.4 Mil.
Cash Flow from Operations was 309.781 + -21.976 + 0.689 + 13.005 = $301.5 Mil.
Revenue was 66.446 + 51.391 + 34.6 + 72.649 = $225.1 Mil.
Gross Profit was 66.446 + 51.391 + 34.6 + 72.649 = $225.1 Mil.
Average Total Assets from the begining of this year (Jun20)
to the end of this year (Jun21) was
(454.278 + 908.628 + 889.936 + 890.64 + 904.87) / 5 = $809.6704 Mil.
Total Assets at the begining of this year (Jun20) was $454.3 Mil.
Long-Term Debt & Capital Lease Obligation was $46.2 Mil.
Total Current Assets was $717.0 Mil.
Total Current Liabilities was $81.5 Mil.
Net Income was -21.227 + -31.036 + -14.282 + -36.288 = $-102.8 Mil.

Revenue was 1.266 + 3.89 + 4.654 + 16.319 = $26.1 Mil.
Gross Profit was 1.266 + 3.89 + 4.654 + 16.319 = $26.1 Mil.
Average Total Assets from the begining of last year (Jun19)
to the end of last year (Jun20) was
(302.549 + 349.514 + 336.201 + 305.242 + 454.278) / 5 = $349.5568 Mil.
Total Assets at the begining of last year (Jun19) was $302.5 Mil.
Long-Term Debt & Capital Lease Obligation was $11.8 Mil.
Total Current Assets was $316.2 Mil.
Total Current Liabilities was $51.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Translate Bio's current Net Income (TTM) was 40.4. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Translate Bio's current Cash Flow from Operations (TTM) was 301.5. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun20)
=40.449/454.278
=0.08904019

ROA (Last Year)=Net Income/Total Assets (Jun19)
=-102.833/302.549
=-0.33988875

Translate Bio's return on assets of this year was 0.08904019. Translate Bio's return on assets of last year was -0.33988875. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Translate Bio's current Net Income (TTM) was 40.4. Translate Bio's current Cash Flow from Operations (TTM) was 301.5. ==> 301.5 > 40.4 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=46.171/809.6704
=0.05702444

Gearing (Last Year: Jun20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun19 to Jun20
=11.751/349.5568
=0.03361685

Translate Bio's gearing of this year was 0.05702444. Translate Bio's gearing of last year was 0.03361685. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun21)=Total Current Assets/Total Current Liabilities
=717.012/81.514
=8.79618225

Current Ratio (Last Year: Jun20)=Total Current Assets/Total Current Liabilities
=316.221/51.766
=6.10866206

Translate Bio's current ratio of this year was 8.79618225. Translate Bio's current ratio of last year was 6.10866206. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Translate Bio's number of shares in issue this year was 80.026. Translate Bio's number of shares in issue last year was 62.282. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=225.086/225.086
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=26.129/26.129
=1

Translate Bio's gross margin of this year was 1. Translate Bio's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun20)
=225.086/454.278
=0.49548074

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun19)
=26.129/302.549
=0.08636287

Translate Bio's asset turnover of this year was 0.49548074. Translate Bio's asset turnover of last year was 0.08636287. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Translate Bio has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Translate Bio  (NAS:TBIO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Translate Bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Translate Bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Translate Bio (Translate Bio) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
Jean Francois Formela director C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr director, officer: Chief Executive Officer, other: President C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess officer: Chief Operating Officer, CLO, other: Secretary C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc. 10 percent owner 300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c. 10 percent owner 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman 10 percent owner 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma 10 percent owner 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge director C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch director
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier officer: Chief Medical Officer 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109